Everolimus

• 

  Subject Areas on Research

  • "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. 
  • A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. 
  • A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. 
  • A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. 
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. 
  • Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. 
  • Clinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy. 
  • Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. 
  • Clinical outcomes in real-world patients with acute myocardial infarction receiving XIENCE V® everolimus-eluting stents: one-year results from the XIENCE V USA study. 
  • Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study. 
  • Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: one year results from the XIENCE V® USA condition of approval post-market study. 
  • Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. 
  • Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. 
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. 
  • Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. 
  • Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. 
  • Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. 
  • Enteric-coated mycophenolate sodium versus mycophenolate mofetil maintenance immunosuppression: outcomes analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network database. 
  • Everolimus in colorectal cancer. 
  • Everolimus tablets for patients with subependymal giant cell astrocytoma. 
  • Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 
  • Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. 
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Long-term experience with everolimus in kidney transplantation in the United States. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • Next-generation drug-eluting stents: a spirited step forward or more of the same. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • Patient-Reported Outcomes in Revascularization Decisions for Left-Main Disease: Sharing the EXCELlence. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. 
  • Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. 
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. 
  • Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. 
  • Sex, Region, and Outcomes After Revascularization. 
  • Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials. 
  • Survival of acute myeloid leukemia cells requires PI3 kinase activation. 
  • Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 
  • Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. 
  • mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. 
  • mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.